About Us: Funds
MPM BioVentures I
(BB BioVentures, MPM BioVentures Parallel Fund)
The $230 million MPM BioVentures I family of funds was raised in 1997. The fund is now fully committed with 75% of the investments in biotechnology and 25% in medical devices and other healthcare related fields. The MPM BioVentures I portfolio is comprised of 26 companies with investments ranging from $5 - $20 million in each portfolio company. Within biotechnology, our investments are split between companies focused on therapeutics and enabling technologies. Roughly 80% of the funds were invested in U.S. companies, 20% in European companies.
MPM BioVentures II
The $600 million MPM BioVentures II family of funds -- which closed in the first quarter of 2000 – comprise a portfolio of investments in biotechnology, medical devices, and other healthcare-related fields. MPM BioVentures II has invested in 35 companies, with investments ranging from $10 - $50 million per company. The fund has invested across the entire spectrum of company development, from start-up through mezzanine and PIPES. 85% of the investments are in U.S. companies, and 15% are in European and Asian companies.
MPM BioVentures III
MPM closed its third venture initiative, the MPM BioVentures III Fund, in December 2002. It is the largest dedicated healthcare venture capital fund ever raised, with committed capital of $940 million. The MPM BioVentures III Fund has a portfolio of 39 companies, 85% focused on biotechnology and pharmaceutical products and 15% focused on medical devices and the life science tool segment. Its balanced portfolio of early, mid- and late-stage companies includes investments in public companies via PIPE transactions.
MPM BioVentures IV
MPM Capital began investing its fourth venture fund, the MPM BioVentures IV Fund, in the second quarter of 2006. With committed capital of $550 million, the MPM BioVentures IV Fund will ultimately comprise a portfolio of approximately 20 companies, with approximately 85% focused on biotechnology and pharmaceutical products and 15% focused on medical device companies. The fund’s preferred investment size ranges from $20 million - $40 million per company. From a geographic perspective, approximately 20% of the fund’s investments have been made outside the U.S., including investments in Asia as well as Europe. The uniquely broad and deep team that has been assembled at MPM Capital to build and manage the fund’s portfolio is characterized not only by its investment and scientific prowess but also by its expertise in building leading clinical and commercial stage companies. MPM BioVentures IV expects to be the lead investor in a majority of its investments and take an active role as board members in the portfolio companies.
MPM BioEquities
The MPM BioEquities Fund is a dedicated biotechnology investment fund designed to provide investors an opportunity to achieve a superior rate of return through investments in public, and to a lesser extent, private biotech companies in the U.S. and abroad. The MPM BioEquities Fund invests with a long bias in emerging biotech on the basis of strong fundamental due diligence. The seamless integration of MPM’s private and public platforms provides unmatched investment resources. The fund is focused in the public markets on the small- and mid-capitalization segment of biotech. Market risk is actively managed by shorting individual companies opportunistically. For private investments, the team largely draws on the exceptional deal flow and expertise of the partners and principals of the MPM BioVentures group.